Identification roles of NFE2L3 in digestive system cancers.
Biomarker
Diagnosis
Digestive system cancers
NFE2L3
Prognosis
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
received:
07
01
2024
accepted:
19
02
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
epublish
Résumé
Morbidity and mortality rates of Digestive System Cancers (DSC) continue to pose human lives and health. Nuclear factor erythroid 2-like protein 3 (NFE2L3) is aberrantly expressed in DSC. This study aimed to explore the clinical value and underlying mechanisms of NFE2L3 as a novel biomarker in DSC. We utilized data from databases and clinical gastric cancer specimens to validate the aberrant expression level of NFE2L3 and further assessed the clinical value of NFE2L3. To investigate the potential molecular mechanism of NFE2L3, we analyzed the correlation of NFE2L3 with immune molecular mechanisms, constructed PPI network, performed GO analysis and KEGG analysis, and finally explored the biological function of NFE2L3 in gastric cancer cells. NFE2L3 expression is up-regulated in DSC and has both prognostic and diagnostic value. NFE2L3 correlates with various immune mechanisms, PPI network suggests proteins interacting with NFE2L3, GSEA analysis suggests potential molecular mechanisms for NFE2L3 to play a role in cancer promotion, and in vitro cellular experiments also confirmed the effect of NFE2L3 on the biological function of gastric cancer cells. Our study confirms the aberrant expression and molecular mechanisms of NFE2L3 in DSC, indicating that NFE2L3 could serve as a novel biomarker for diagnosis and prognosis of DSC.
Sections du résumé
BACKGROUND
BACKGROUND
Morbidity and mortality rates of Digestive System Cancers (DSC) continue to pose human lives and health. Nuclear factor erythroid 2-like protein 3 (NFE2L3) is aberrantly expressed in DSC. This study aimed to explore the clinical value and underlying mechanisms of NFE2L3 as a novel biomarker in DSC.
METHODS
METHODS
We utilized data from databases and clinical gastric cancer specimens to validate the aberrant expression level of NFE2L3 and further assessed the clinical value of NFE2L3. To investigate the potential molecular mechanism of NFE2L3, we analyzed the correlation of NFE2L3 with immune molecular mechanisms, constructed PPI network, performed GO analysis and KEGG analysis, and finally explored the biological function of NFE2L3 in gastric cancer cells.
RESULTS
RESULTS
NFE2L3 expression is up-regulated in DSC and has both prognostic and diagnostic value. NFE2L3 correlates with various immune mechanisms, PPI network suggests proteins interacting with NFE2L3, GSEA analysis suggests potential molecular mechanisms for NFE2L3 to play a role in cancer promotion, and in vitro cellular experiments also confirmed the effect of NFE2L3 on the biological function of gastric cancer cells.
CONCLUSION
CONCLUSIONS
Our study confirms the aberrant expression and molecular mechanisms of NFE2L3 in DSC, indicating that NFE2L3 could serve as a novel biomarker for diagnosis and prognosis of DSC.
Identifiants
pubmed: 38514488
doi: 10.1007/s00432-024-05656-y
pii: 10.1007/s00432-024-05656-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
150Subventions
Organisme : National Natural Science Foundation of China
ID : 82070594
Organisme : National Natural Science Foundation of China
ID : 82070594
Informations de copyright
© 2024. The Author(s).
Références
Arimont M, Sun SL, Leurs R, Smit M, de Esch IJP, de Graaf C (2017) Structural analysis of chemokine receptor-ligand interactions. J Med Chem 60:4735–4779
doi: 10.1021/acs.jmedchem.6b01309
pubmed: 28165741
pmcid: 5483895
Asaoka Y, Ijichi H, Koike K (2015) PD-1 blockade in tumors with mismatch repair deficiency. N Engl J Med 373:1979. https://doi.org/10.1056/NEJMc1510353
doi: 10.1056/NEJMc1510353
pubmed: 26559583
Baharom F, Ramirez-Valdez RA, Khalilnezhad A, Khalilnezhad S, Dillon M, Hermans D (2022) Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment. Cell 185:4317–4332. https://doi.org/10.1016/j.cell.2022.10.006
doi: 10.1016/j.cell.2022.10.006
pubmed: 36302380
pmcid: 9669246
Bravaccini S, Bronte G, Ulivi P (2021) TMB in NSCLC: a broken dream? Int J Mol Sci 22:6356. https://doi.org/10.3390/ijms22126536
doi: 10.3390/ijms22126536
Bury M, Le Calvé B, Lessard F, Dal Maso T, Saliba J, Michiels C, Gerardo F, Blank V (2019a) NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor. Cell Rep 29:1469–1481. https://doi.org/10.1016/j.celrep.2019.09.087
doi: 10.1016/j.celrep.2019.09.087
pubmed: 31693889
Bury M, Le Calvé B, Lessard F, Dal Maso T, Saliba J, Michiels C, Ferbyre G, Blank V (2019b) NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 Inhibitor. Cell Rep 29(6):1469–1481. https://doi.org/10.1016/j.celrep.2019.09.087
doi: 10.1016/j.celrep.2019.09.087
pubmed: 31693889
Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398:1002–1014. https://doi.org/10.1016/S0140-6736(21)01206-X
doi: 10.1016/S0140-6736(21)01206-X
pubmed: 34509219
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Perters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30:44–56. https://doi.org/10.1093/annonc/mdy495
doi: 10.1093/annonc/mdy495
pubmed: 30395155
Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621. https://doi.org/10.1056/NEJMra052723
doi: 10.1056/NEJMra052723
pubmed: 16467548
Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8:e000957. https://doi.org/10.1136/jitc-2020-000957
doi: 10.1136/jitc-2020-000957
pubmed: 32900861
pmcid: 7477968
Chen LB, Lu DW, Sun KK, Xu YM, Hu PP, Li XP (2019) Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis. Gene 692:119–125. https://doi.org/10.1016/j.gene.2019.01.001
doi: 10.1016/j.gene.2019.01.001
pubmed: 30654001
Chevillard G, Blank V (2011) NFE2L3 (NRF3): the cinderella of the cap’n’collar transcription factors. Cell Mol Life Sci 68:3337–3348. https://doi.org/10.1007/s00018-011-0747-x
doi: 10.1007/s00018-011-0747-x
pubmed: 21687990
Datta N, Chakraborty S, Basu M, Ghosh MK (2020) Tumor suppressors having oncogenic functions: the double agents cells. Cells 10:46. https://doi.org/10.3390/cells10010046
doi: 10.3390/cells10010046
pubmed: 33396222
pmcid: 7824251
De Angelis GL, Bottarelli L, Azzoni C, De Angelis N, Leandro G, Di Mario F, Gaiani F, Negri F (2018). Microsatellite instability in colorectal cancer. Acta Biomed, doi: https://doi.org/10.23750/abm.v89i9-S.7960
Feng M, Zhao Z, Yang M, Ji J, Zhu D (2021) T-cell-based immunotherapy in colorectal cancer. Cancer Lett 498:201–209. https://doi.org/10.1016/j.canlet.2020.10.040
doi: 10.1016/j.canlet.2020.10.040
pubmed: 33129958
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 17:725–741. https://doi.org/10.1038/s41571-020-0413-z
doi: 10.1038/s41571-020-0413-z
pubmed: 32760014
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16:361–375. https://doi.org/10.1038/s41575-019-0126-x
doi: 10.1038/s41575-019-0126-x
pubmed: 30886395
pmcid: 7295073
Ju Q, Li XM, Zhang H, Yan S, Li Y, Zhao YJ (2020) NFE2L2 is a potential prognostic biomarker and is correlated with immune infiltration in brain lower grade glioma: a pan-cancer analysis. Oxid Med Cell Longev 2020:3580719. https://doi.org/10.1155/2020/3580719
doi: 10.1155/2020/3580719
pubmed: 33101586
pmcid: 7569466
Kamada TH, Togashi YK, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Skaguchi S, Nishikawa H (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA 116:9999–10008. https://doi.org/10.1073/pnas.1822001116
doi: 10.1073/pnas.1822001116
pubmed: 31028147
pmcid: 6525547
Lacalle RA, Blanco R, Carmona-Rodríguez L, Martín-Leal A, Mira E, Mañes S (2017) Chemokine receptor signaling and the hallmarks of cancer. Int Rev Cell Mol Biol 331:181–244. https://doi.org/10.1016/bs.ircmb.2016.09.011
doi: 10.1016/bs.ircmb.2016.09.011
pubmed: 28325212
Liang YF, Meng KY, Qiu R (2021) Circular RNA Circ_0013958 functions as a tumor promoter in ovarian cancer by regulating miR-637/PLXNB2 axis. Front Genet 12:644451. https://doi.org/10.3389/fgene.2021.644451
doi: 10.3389/fgene.2021.644451
pubmed: 34367233
pmcid: 8334736
Lin A, Zhang J, Luo P (2020) Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol 2020(11):2039. https://doi.org/10.3389/fimmu.2020.02039
doi: 10.3389/fimmu.2020.02039
Pe’er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D (2021) Tumor heterogeneity. Cancer Cell 39:1015–1017. https://doi.org/10.1016/j.ccell.2021.07.009
doi: 10.1016/j.ccell.2021.07.009
pubmed: 34375606
Peng S, Chen S, Hu W, Mei J, Zeng XZ, Su TH, Wang W, Chen ZB, Xiao H, Zhou Q, Li B, Xie YB, Hu HJ, He MH, Han YY, Tang LQ, Ma YF, Li XH, Zhou XJ, Dan ZH, Liu ZL, Tan JH, Xu LX (2022) Combination neoantigen-based dendritic cell vaccination and adoptive t-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res 10:728–744. https://doi.org/10.1158/2326-6066.CIR-21-0931
doi: 10.1158/2326-6066.CIR-21-0931
pubmed: 35476700
Qian JQ, Huang C, Zhu Z, He YH, Wang Y, Feng N, He SM, Li XS, Zhou LQ, Zhang CJ, Gong YQ (2022) NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer. Carcinogenesis 43:457–468. https://doi.org/10.1093/carcin/bgac006
doi: 10.1093/carcin/bgac006
pubmed: 35022660
Ratnam NM, Gilbert MR, Giles AJ (2019) Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro Oncol 21:37–46. https://doi.org/10.1093/neuonc/noy084
doi: 10.1093/neuonc/noy084
pubmed: 29771386
Ren YG, Wang YJ, Hao S, Yang YH, Xiong WD, Qiu L, Tao J, Tang A (2020) NFE2L3 promotes malignant behavior and EMT of human hepatocellular carcinoma (HepG2) cells via Wnt/β-catenin pathway. J Cancer 11:6939–6949. https://doi.org/10.7150/jca.48100
doi: 10.7150/jca.48100
pubmed: 33123284
pmcid: 7591994
Saliba J, Coutaud B, Makhani K, Epstein Roth N, Jackson J, Park JY, Gagnon N, Costa P, Jeyakumar T, Bury M, Beauchemin N (2022) Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment. Oncogene 41:1563–1575. https://doi.org/10.1038/s41388-022-02192-2
doi: 10.1038/s41388-022-02192-2
pubmed: 35091681
pmcid: 8913363
Schmall A, Al-Tamari HM, Herold S, Kampschulte M, Weigert A, Wietelmann A, Vipotnik N, Grimminger F, Seeger W, Pullamsetti SS, Savai R (2015) Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med 191:437–447. https://doi.org/10.1164/rccm.201406-1137OC
doi: 10.1164/rccm.201406-1137OC
pubmed: 25536148
Sekine H, Motohashi H (2021) Roles of CNC transcription factors NRF1 and NRF2 in cancer. Cancers (basel) 13:541. https://doi.org/10.3390/cancers13030541
doi: 10.3390/cancers13030541
pubmed: 33535386
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654
doi: 10.3322/caac.21654
pubmed: 33433946
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhar J, Schill C, Hess C, Princetrans SS, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A (2018) Tcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24:994–1004. https://doi.org/10.1038/s41591-018-0057-z
doi: 10.1038/s41591-018-0057-z
pubmed: 29892065
pmcid: 6110381
Tomlinson I, Halford S, Aaltonen L, Hawkins N, Ward R (2002) Does MSI-low exist? J Pathol 197:6–13. https://doi.org/10.1002/path.1071
doi: 10.1002/path.1071
pubmed: 12081205
Waku T, Katayama H, Hiraoka M, Hatanaka A, Nakamura N, Tanaka Y, Tamura N, Wantanabe A, Kobayashi A (2020) NFE2L1 and NFE2L3 Complementarily maintain basal proteasome activity in cancer cells through CPEB3-mediated translational repression. Mol Cell Biol 40:e00010–e00020. https://doi.org/10.1128/MCB.00010-20
doi: 10.1128/MCB.00010-20
pubmed: 32366381
pmcid: 7324849
Wang H, Zhan M, Yang RM, Shi YH, Liu Q (2018) Wang J. Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. Cell Cycle 17:2164–2174. https://doi.org/10.1080/15384101.2018.1520558/
doi: 10.1080/15384101.2018.1520558/
pubmed: 30196752
pmcid: 6226237
Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, Yuzhou W (2020) Lactic Acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci 2020:21. https://doi.org/10.3390/ijms21218363
doi: 10.3390/ijms21218363
Xie FF, You YL, Huang JH, Guan C, Chen ZJ, Fang M, Yao F (2021) Association between physical activity and digestive-system cancer: an updated systematic review and meta-analysis. J Sport Health Sci 10:4–13. https://doi.org/10.1016/j.jshs.2020.09.009
doi: 10.1016/j.jshs.2020.09.009
pubmed: 33010525
Xu-Monette ZY, Zhou JF (2018) Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68–83. https://doi.org/10.1182/blood-2017-07-740993
doi: 10.1182/blood-2017-07-740993
pubmed: 29118007
pmcid: 5755041
Zeng X, Ju DW (2018) Hedgehog signaling pathway and autophagy in cancer. Int J Mol Sci 19:2279. https://doi.org/10.3390/ijms19082279
doi: 10.3390/ijms19082279
pubmed: 30081498
pmcid: 6121518
Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, Wu MJ, Wainwright DA (2018) IDO1 in cancer: a gemini of immune checkpoints. Cell Mol Immunol 15:447–457. https://doi.org/10.1038/cmi.2017.143
doi: 10.1038/cmi.2017.143
pubmed: 29375124
pmcid: 6068130
Zhang YG, Kobayashi A, Yamamoto MK, Hayes JD (2009) The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence. J Biol Chem 284:3195–3210. https://doi.org/10.1074/jbc.M805337200
doi: 10.1074/jbc.M805337200
pubmed: 19047052
Zhang LH, Hu DL, Tang B, Cheng Y, Jiao C, Cheng L, Tan ZR, Zhou HH (2019) NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in colorectal cancer cells through downregulating CCND1 and pRb1-ser807/811. Dis Markers. https://doi.org/10.1155/2019/2829798
doi: 10.1155/2019/2829798
pubmed: 31976024
pmcid: 6954481
Zhang Q, Tang D, Zha A, He JQ, Li DD, Chen YM, Cai WX, Dai J, Luan SD, Yin LH, Zhang W, Dai Y (2022) NFE2L3 as a potential functional gene regulating immune microenvironment in human kidney cancer. Biomed Res Int 2022:9085186. https://doi.org/10.1155/2022/9085186
doi: 10.1155/2022/9085186
pubmed: 36337840
pmcid: 9629961